SkyCell partners with Air France KLM Martinair Cargo to provide ULD tracking and visibility

                   SkyCell, the purpose-led technology company transforming the pharmaceutical supply chain, has been selected by Air France KLM Martinair Cargo as its preferred unit load device (ULD) tracking partner. This latest partnership will see SkyCell deploy its state of the art, built for purpose IoTs across Air France KLM Martinair Cargo’s entire ULD fleet; providing the airline group with real-time visibility into its ULD operations on the SkyMind platform and driving significant operational and cost efficiencies.

The partnership comes as demand grows for cost-effective ULD solutions, as the combined expenses related to ULD loss and repair are estimated to reach USD 330 million worldwide annually. With SkyMind, Air France KLM Martinair Cargo gains complete control over ULD operations — mitigating the extensive manual efforts historically associated with tracing and tracking, leading to substantial time and cost savings, as well as boosting operational efficiency.

SkyMind utilises state-of-the-art technology, including advanced readers and tags, to provide airlines with real-time visibility into their entire ULD fleet. This visibility enables airlines to make informed decisions and operate proactively rather than reactively, resulting in improved operational efficiency. 

Nico Ros, CTO and co-founder SkyCell:  “We’re excited about our partnership with Air France KLM Martinair Cargo as we establish a new standard in technology for Air Cargo’s ULD (Unit Load Device) management. This achievement is made possible through our close cooperation with Air France KLM Martinair Cargo and the integration of SkyMind, our IoT-driven visibility platform with specialised ULD management. The partnership marks a major transformation in the airline industry towards automation, with a strong focus on efficient ULD management, streamlined dispositioning and improved asset utilisation.”

Adriaan den Heijer, EVP Air France-KLM Cargo and Managing Director Martinair:  “We’ve decided to invest in the latest asset tracking technology with SkyCell. A new technology solution, called SkyMind, has been developed. Implementing state-of-the-art tracking devices to locate our ULDs will not only enable us to track our assets but will also significantly enhance our operational quality. Real-time ULD tracking will enable us to address the issue of ULD losses, whether by ground handling partners or our valued customers, and will ensure seamless movement of cargo. With improved ULD management, we can optimise our operations and deliver exceptional service to our air cargo industry partners.”

A Zeno.FM Station

SkyCell partners with Marken to enhance the pharmaceutical transport of products for clinical trials

SkyCell, the innovator and leading manufacturer of temperature-controlled hybrid containers for the pharmaceutical industry, has partnered with Marken to provide advanced shipping solutions for clinical trials pharmaceutical products. The collaboration will provide Marken, the clinical trials logistics subsidiary of UPS Healthcare, with SkyCell containers to ship critical and temperature-sensitive drugs. 

Marken will use two different SkyCell containers - the 1500DF Euro Max and the 1500X. The 1500DF Euro Max provides up to 300h of temperature stability for frozen goods (-60℃ to -80℃). The 1500X has an independent runtime of up to 270h for COL goods (+2℃ to +8℃) and CRT goods (+15℃ to +25℃), with the added ability to recharge containers in transit. The containers are 34.1 percent lighter than comparable containers and with their long runtime are able to transport delicate products for clinical trials anywhere around the world.

SkyCell achieves goal of running solely on renewable energy in continued pursuit of net-zero emissions by 2040

SkyCell, the innovator and leading manufacturer of temperature-controlled hybrid containers for the pharmaceutical industry, has released its second annual Sustainability Report, detailing the progress made in achieving net-zero emissions within the entire supply chain and making pharma supply chains more sustainable. In 2021, the Swiss company successfully transitioned their operations to run solely on renewable electricity. 

The healthcare industry is a significant contributor of global CO2 emissions, emitting two gigatons of CO2 emissions annually, the equivalent of being the fifth-largest emitting country globally. For pharma companies, supply chains represent a sizable proportion of these emissions. Reducing Scope 3 emissions is considered the most challenging as they fall outside of the company’s direct operational control. In 2021, SkyCell’s overall Scope 3 emissions intensity decreased by 8%, which was achieved by optimizing shipment routes, minimizing empty transports, and shifting towards more sustainable modes of transport. 

Reducing the carbon intensity of its shipments has been a key pillar of the company’s emissions reduction plan. SkyCell has made notable strides thanks to the continued improvement of its container design, material use, and production process, which had already been found to reduce emissions by up to 50% compared to other pharma containers. SkyCell’s newest container, the 1500X, has achieved even greater weight and space efficiencies, weighing 379kg which is significantly less than the 630kg+ of active containers on the market today.

SkyCell and Japan Airlines partner to support the growing Japanese pharmaceutical shipment market

 SkyCell, the manufacturer of innovative hybrid pharmaceutical containers, has partnered with Japan Airlines Cargo (JAL Cargo), to meet the country's growing needs for vaccine and pharmaceutical transportation in a safe, secure, and sustainable way.

SkyCell is committed to working with JAL Cargo to offer a tailor-made solution that meets the airline's growing business needs across vaccine and pharmaceutical shipments. This partnership will also see SkyCell further strengthen its presence in Japan and continue to support the temperature-sensitive pharmaceutical market with its high-quality hybrid containers that have been industry accredited to have near-zero spoilage rates.

SkyCell’s GDP compliant hybrid containers - which maintain internal temperature stability across the pharmaceutical industry recognised temperature ranges, without the need for external intervention - are able to cover customers’ various needs. By using lightweight, environmentally friendly material, the technology enables efficiency and reusability. The Swiss-engineered hybrid features include shock-absorbent feet to mitigate any breakage during transport and has a double-door system to protect the packing against humidity. 

The partnership between SkyCell and JAL is a first step into a joint vision to determinedly, faithfully, and creatively increase the shipment quality of highly valuable and sensitive products.

Chiara Venuti, Business Development Director and Airline Partners, SkyCell, comments: “I see this partnership with JAL as a firm commitment from SkyCell to support the Japanese pharmaceutical market. We play a key role together in delivering life-saving medicine in the most safe, secure, and sustainable way to the patients in need. A great journey starts with small steps, and we look forward to working together with a common mission focused on ensuring patients get the life-saving medicines they need in a sustainable and secure way.”   

Hidehiko Umehara, Vice President, Business Promotion Department, JAL Cargo comments: “On the signing of a Master Lease Agreement, JAL and SkyCell will work in close cooperation and coordination to provide our customers with peace of mind when using SkyCell containers, which have a temperature excursion rate of less than 0.1% and are capable of maintaining the required temperature range at the highest levels, and do not need electric power.”

More top stories you might be interested in.....

Follow this site here.

SkyCell expands reach with All Nippon Airways partnership to support growing import needs in Japan

SkyCell, the manufacturer of innovative hybrid pharmaceutical containers, has partnered with All Nippon Airways (ANA), Japan's largest airline, to help support pharmaceutical customers shipping in and out of Japan in a safe, secure, and sustainable way. 

The partnership with SkyCell will also see the airline reach more of its sustainability goals. ANA expects there to be stronger demand for sustainability in the future, and can offer its customers more sustainable shipping options through SkyCell.

SkyCell currently has one service centre in Japan that will support the Japanese market with container availability in the country.

SkyCell will be supporting ANA with its dedicated pharmaceutical containers across different temperature ranges to cover customers’ various needs. SkyCell containers maintain internal temperature stability in external conditions from as low as -30°C to as high as +70°C. The complete temperature range includes the deep-frozen container that is able to maintain internal temperatures between -80°C and -60°C for extended periods of time. Thanks to the innovative technology of SkyCell, ANA will be able to utilise full aircraft capacity, mitigating the traditional capacity limitations caused by the use of dry ice by making energy transfer more efficient.

SkyCell launches annual sustainability report; commits to reach carbon neutral by 2040

According to the Journal of Cleaner Production, the pharmaceutical industry’s emission intensity is 55% higher than that of the automotive industry, signalling the desperate need for action 

SkyCell, the leading manufacturer of innovative pharma containers, is publicly announcing its sustainability and carbon neutrality goals and its progress towards them in its first annual Sustainability Report. The Swiss company, whose containers’ CO2 emissions are already about half the industry standard due to technological innovation and sustainability-focused product design, wants to lead the way to a more sustainable pharmaceutical supply chain and help counter the mounting climate crisis. Through its ambitious goals focused on climate, circularity, and cooperation, SkyCell commits to reaching fully carbon neutrality by 2040.  

Since its creation in 2012, SkyCell has held Environmental, Sustainability and Governance (ESG) at the core of its operations. As part of its commitment to the UN Sustainable Development Goals and the Paris Agreement, SkyCell is strengthening its efforts to reduce greenhouse gasses by setting itself ambitious goals. 

   

These include running solely on renewable energies by the end of 2021 and reducing direct emissions from SkyCell’s operations, and indirect ones related to the energy used for the company’s activities, by 50% by 2030. SkyCell’s ultimate goal is to achieve full carbon neutrality by 2040, with minimal use of carbon certificates.* To further help the company reach its ambitious goal, SkyCell is exploring technological innovation through various partnerships such as with Swiss start-up, Airborn Fuels, to produce jet fuel out of CO2 and renewable energy.

SkyCell and Etihad Cargo - working together to transport temperature-controlled pharmaceuticals in a safe, secure, and sustainable way.

Photo Etihad Cargo

SkyCell is one of the global leaders in the field of manufacturing data-driven temperature-controlled containers for the pharmaceutical industry. Etihad Cargo is the cargo and logistics arm of the mammoth and award-winning Etihad Aviation Group.  So it, therefore, seems such a natural fir for the two companies to work in partnership to bring customers a wide range of solutions to transport their temperature-controlled pharmaceuticals in a safe, secure, and sustainable way. 

SkyCell’s highly innovative hybrid containers will allow Etihad Cargo to optimise its supply chains by using data to predict and control risk. More than three-quarters of a billion data-points are available on factors like temperature, location, and time, the SkyCell containers also enable a failure rate of less than 0.1 per cent, while reducing CO2 emissions by almost half. 

 Both companies are committed to implementing sustainable practices across the pharma supply chain through SkyCell’s innovative hybrid containers and optimisation solutions

Photo SkyCell

Tracked with IoT (‘Internet of Things’) sensors, hybrid containers monitor the temperature conditions inside and outside the containers to ensure the full efficacy of pharmaceuticals is maintained until they reach patients. In the process, SkyCell’s containers both reduce a shipment’s carbon footprint by up to 50 per cent due to their lightweight and efficient design. The containers are also capable of charging independently without the need of human intervention, and help reduce the amount of medical waste that ends up in landfill due to throw-away solutions and product loss caused by temperature excursions. 

 

Etihad Cargo and SkyCell sustainably transport life-saving pharmaceuticals

Photo Etihad Cargo

SkyCell is one of the global leaders in the field of manufacturing data-driven temperature-controlled containers for the pharmaceutical industry. Etihad Cargo is the cargo and logistics arm of the mammoth and award-winning Etihad Aviation Group.  So it, therefore, seems such a natural fir for the two companies to work in partnership to bring customers a wide range of solutions to transport their temperature-controlled pharmaceuticals in a safe, secure, and sustainable way. 

SkyCell’s highly innovative hybrid containers will allow Etihad Cargo to optimise its supply chains by using data to predict and control risk. More than three-quarters of a billion data-points are available on factors like temperature, location, and time, the SkyCell containers also enable a failure rate of less than 0.1 per cent, while reducing CO2 emissions by almost half. 

 Both companies are committed to implementing sustainable practices across the pharma supply chain through SkyCell’s innovative hybrid containers and optimisation solutions

Photo SkyCell

Tracked with IoT (‘Internet of Things’) sensors, hybrid containers monitor the temperature conditions inside and outside the containers to ensure the full efficacy of pharmaceuticals is maintained until they reach patients. In the process, SkyCell’s containers both reduce a shipment’s carbon footprint by up to 50 per cent due to their lightweight and efficient design. The containers are also capable of charging independently without the need of human intervention, and help reduce the amount of medical waste that ends up in landfill due to throw-away solutions and product loss caused by temperature excursions. 

 

LATAM Cargo Group partners with SkyCell to bring innovative hybrid container solutions to South American pharmaceutical market

SkyCell containers will be used to ship pharmaceuticals across key countries such as Chile, Brazil, and Argentina and help the South American airline expanding its pharma services.

SkyCell, the leading manufacturer of temperature-controlled containers, has partnered with LATAM Cargo Group to help ship pharmaceuticals to South America in a secure, safe, and sustainable way. This partnership comes at a crucial time for the pharmaceutical industry in South America, as the PHARMA volumes being transported by LATAM this year has more than doubled, compared to the same period in 2020. 

LATAM Cargo Group has the network and the expertise the pharmaceutical market requires for South America, and its use of SkyCell’s innovative container solutions through this partnership will help ensure these life-saving biologics make it to their destination in pristine condition. 

LATAM Cargo's partnership with SkyCell will help increase supply chain reliability and flexibility by ensuring cargo is kept at the optimal temperature throughout its journey, monitored by SkyCell's IoT and Lane Risk Assessment technology. 

LOT Polish Airlines and SkyCell, sign an agreement that extending LOT Cargo’s capabilities in the transport of medicines and pharmaceutical products (PIL).

 

LOT Polish Airlines and SkyCell, a Swiss provider of hybrid containers, signed an agreement that extends LOT Cargo’s capabilities in the transport of medicines and pharmaceutical products (PIL). 

Thanks to advanced technology, SkyCell’s hybrid containers guarantee to maintain a constant transport temperature necessary for transporting demanding shipments even to  distant regions of the world.

The transport of pharmaceutical products requires the airlines to apply specialist solutions and meet demanding standards guaranteeing safety and the highest quality of provided services. Pharma and Life-Science is a critical sector of global cargo transport for LOT; therefore, the company is constantly increasing its competencies and improving its offer addressed to companies operating in this industry. 

In July 2020, LOT Cargo obtained the IATA CEIV Pharma certificate, which gave the Polish carrier a place in the prestigious group of 25 airlines with a documented and approved PIL QMS Quality Management System for pharmaceutical shipment management.

SkyCell and DB Schenker sign new partnership deal

DB Schenker increases response to the pandemic by signing a Master Lease Agreement (MLA) with SkyCell. The partnership enables DB Schenker to enhance its vaccine logistics service solutions with additional flexibility through the new healthcare product DB SCHENKERlife+. Based in Switzerland, SkyCell manufactures innovative temperature-controlled air freight containers for pharmaceutical supply chains that can maintain internal temperatures as low as -80°C to -15°C for a minimum of five days, and temperatures of +2°C to +8°C and +15°C to +25°C for more than eight days. As part of the new partnership with SkyCell, DB Schenker’s service portfolio is extended by an additional reliable packaging solution to transport lifesaving pharmaceutical products, such as vaccines against Covid-19, globally. 

Milestone agreement for the lease of SkyCell’s hybrid pharma containers • Containers maintain constant temperatures for more than a week • Suitable for all Covid-19 vaccines on the market 

Thorsten Meincke, Global Board Member for Air & Ocean Freight at DB Schenker: “Logistics matters extensively in trying to overcome the pandemic and DB Schenker is already transporting Covid-19 vaccines worldwide. With this agreement, we upgrade our existing broad portfolio of healthcare-related logistics services with even more capability for our customers for the widespread roll-out of global vaccinations. With SkyCell, we have found an excellent partner in this endeavor to provide high quality on a global level.” 

DB Schenker signs partnership with SkyCell: Temperature-controlled containers for lifesaving medicine and Covid-19 vaccines

DB Schenker increases response to the pandemic by signing a Master Lease Agreement (MLA) with SkyCell. The partnership enables DB Schenker to enhance its vaccine logistics service solutions with additional flexibility through the new healthcare product DB SCHENKERlife+. Based in Switzerland, SkyCell manufactures innovative temperature-controlled air freight containers for pharmaceutical supply chains that can maintain internal temperatures as low as -80°C to -15°C for a minimum of five days, and temperatures of +2°C to +8°C and +15°C to +25°C for more than eight days. As part of the new partnership with SkyCell, DB Schenker’s service portfolio is extended by an additional reliable packaging solution to transport lifesaving pharmaceutical products, such as vaccines against Covid-19, globally. 

Milestone agreement for the lease of SkyCell’s hybrid pharma containers • Containers maintain constant temperatures for more than a week • Suitable for all Covid-19 vaccines on the market 

Thorsten Meincke, Global Board Member for Air & Ocean Freight at DB Schenker: “Logistics matters extensively in trying to overcome the pandemic and DB Schenker is already transporting Covid-19 vaccines worldwide. With this agreement, we upgrade our existing broad portfolio of healthcare-related logistics services with even more capability for our customers for the widespread roll-out of global vaccinations. With SkyCell, we have found an excellent partner in this endeavor to provide high quality on a global level.” 

Virgin Atlantic to ship vaccines through partnership with SkyCell

Virgin Atlantic’s Pharma service will use SkyCell’s temperature-controlled containers to ship valuable, life-saving pharmaceuticals

                                       SkyCell, one of the leading manufacturers of innovative pharma containers, has partnered with Virgin Atlantic to contribute to its safe, secure, and sustainable shipment of valuable vaccines and pharma products. Virgin Atlantic will use SkyCell containers covering the full range of biologics transit temperature requirements: -80°C, -25°C to -15°C, +2°C to +8°C, and up to +15°C to + 25°C.

The partnership will give customers confidence that their pharmaceutical shipments will arrive at destination safely, as the innovative hybrid containers - which have an average runtime of 202 hours - have a failure rate of less than 0.1%. This is compared to an industry standard failure rate of up to 12%, which cost the pharma industry $34.1 billion in 2019 alone.